This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week, we discuss the latest from CRIC, an examination of NSAIDs versus opioids for patients with CKD. Join us May 12 and 13th to discuss with #NephJC.
In conjunction with NephMadness - Pain Region discussion, we discuss a recent JAMA Network Open study, reporting higher kidney risk in young men taking NSAIDs.
There is AKI. You are ready to discharge the patient. Should you restart their ACEI/ARB? Or they were never on an ACEI/ARB - but surely with a history of heart failure, they should be on one? How do you decide? Join us to discuss some exciting new data
This week, we will discuss an observational study - a very large series of using DDAVP for treatment of hyponatremia. Yes, you read that right. Read the paper for free thanks to Am J Med and join us on March 27/28 to discuss.